# Junson Capital

> Junson Capital is a VC fund backing Health Care and Biotechnology. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 19
- Last investment: May 2026
- Lead investor: 16%
- Last updated: Aug 2026

Junson Capital is a private equity investment firm.

## Contacts

5 contacts available for Junson Capital. Shizune tracks 1 team members at Junson Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/junson-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 37% |
| Biotechnology | 5 | 26% |
| Medical | 2 | 11% |
| Security | 2 | 11% |
| Manufacturing | 2 | 11% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 37% |
| Seed | 2 | 11% |
| Series A | 2 | 11% |
| Series C | 2 | 11% |
| Debt Financing | 1 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 42% |
| China | 2 | 11% |
| Israel | 2 | 11% |
| United Kingdom | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kevin Liu | CEO | 0 | https://shizune.co/investors/profile/kevin-liu-72f1 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $109M | Series D | May 18, 2026 |  |
| Butterfly Medical | Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can beplaced in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe.Visit www.butterfly-medical.com for more information. | $21M | Series C | May 14, 2026 |  |
| Wallaby Medical | Wallaby Medical is a manufacturing company that produces Avenir coil systems and medical devices for stroke treatment. |  | Series C | Mar 17, 2026 |  |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $50M | Series C | Sep 29, 2025 |  |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $47.3M | Series B | Jan 03, 2024 |  |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $16M | Debt Financing | Jan 03, 2024 |  |
| Corsair Pharma | Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients. | $23M | Series B | Sep 20, 2023 |  |
| Allotex | Allotex offers therapeutic solutions for the treatment of presbyopia and hyperopia. | $30M | Series B | Jul 09, 2023 |  |
| Worg Pharmaceuticals | Worg Pharmaceuticals is a clinical stage biopharmaceutical company developing new treatments for allergy and other diseases. | $57.5M | Series B | Sep 14, 2022 |  |
| BridGene Biosciences | BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $38.5M | Series B | Jul 27, 2022 |  |

10 of 19 investments shown.

## Co-investors
- [Chengwei Capital](https://shizune.co/investors/profile/chengwei-capital) — VC Fund, 4 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 4 deals together
- [Plaisance Capital Management](https://shizune.co/investors/profile/plaisance-capital-management) — VC Fund, 3 deals together
- [Prosperity7 Ventures](https://shizune.co/investors/profile/prosperity7-ventures-d527) — VC Fund, 3 deals together
- [Sky9 Capital](https://shizune.co/investors/profile/sky9-capital) — VC Fund, 3 deals together
- [Summer Capital](https://shizune.co/investors/profile/summer-capital-ee67) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Junson Capital invest in?

Junson Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Junson Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Junson Capital?

The team at Junson Capital includes Kevin Liu (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co